insulin and glp-1 agonist combination Targeting GLP-1, GIP & GCG in Obesity Type 2 Diabetes Research Cardiophilia - This image is

In clinical trials, it led to a weight reduction of up to 16.2%

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk

Compare every GLP-1 drug for weight loss, see clinical results, and find out which is right for you.

As 2025 gets underway, we take a look at what lies ahead for the highly dynamic market for effective anti-obesity medications (AOMs)

Indias pharma industry is strong

Summary GLP-1 RAs offer a multifaceted therapeutic strategy in PD, targeting both central neurodegenerative processes and peripheral metabolic dysfunction